Timon Vandamme

Timon Vandamme

Wilrijk, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Journal: BMC cancer
Published: June 13, 2026

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 07, 2026

Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence.

Germline MEN1 testing patterns in patients with neuroendocrine tumors: A 12-year retrospective analysis within NETwerk, an ENETS center of excellence.

Journal: Journal of neuroendocrinology
Published: March 19, 2026

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study.

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study.

Journal: International journal of cancer
Published: January 20, 2026

Clamp the LAMP: a photoelectrochemical platform for KRAS mutation detection via wild-type blocking.

Clamp the LAMP: a photoelectrochemical platform for KRAS mutation detection via wild-type blocking.

Journal: Biosensors & bioelectronics
Published: December 15, 2025

The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients.

The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients.

Journal: Cancer research communications
Published: October 24, 2025

Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO).

Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO).

Journal: BMC cancer
Published: September 05, 2025

Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis.

Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis.

Journal: British journal of cancer
Published: August 11, 2025

STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study.

STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study.

Journal: BMJ open
Published: July 16, 2025

The prevalence and clinical significance of 68Ga-DOTANOC incidentaloma.

The prevalence and clinical significance of 68Ga-DOTANOC incidentaloma.

Journal: Endocrine-related cancer
Published: July 14, 2025

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol.

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol.

Journal: BMJ open
Published: July 04, 2025

Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms - experience from NETwerk, a Belgian ENETS Center of Excellence.

Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms - experience from NETwerk, a Belgian ENETS Center of Excellence.

Journal: Acta gastro-enterologica Belgica
Published: June 12, 2025
Showing 1-12 of 69

Last Updated: 09/26/2026